BRAF/MEK inhibitors for BRAF V600E-mutant cancers in non-approved setting: a case series
We report five cases of BRAF V600E (substitution of glutamic acid for valine in codon 600) aberrant refractory metastatic cancers treated with dual BRAF/MEK combination inhibitor therapy leading to an excellent clinical and radiological response and protracted duration of disease control.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Colon Cancer | Colorectal Cancer | Drugs & Pharmacology | Lung Cancer | Melanoma | Non-Small Cell Lung Cancer | Sarcomas | Skin Cancer